Ratio of Omega-6/Omega-3 Polyunsaturated Fatty Acids Associated With Somatic and Depressive Symptoms in People With Painful Temporomandibular Disorder and Irritable Bowel Syndrome.
Epidemiology
idiopathic pain
lipidomics
omega-6/omega-3 PUFA ratio
psychological distress
Journal
The journal of pain
ISSN: 1528-8447
Titre abrégé: J Pain
Pays: United States
ID NLM: 100898657
Informations de publication
Date de publication:
10 2022
10 2022
Historique:
received:
10
02
2022
revised:
24
03
2022
accepted:
07
04
2022
pubmed:
28
4
2022
medline:
12
10
2022
entrez:
27
4
2022
Statut:
ppublish
Résumé
Somatic symptom disturbance is among the strongest predictors of painful temporomandibular disorder (TMD). Related psychological constructs, such as anxiety and depression, respond therapeutically to omega-3 polyunsaturated fatty acids (PUFAs) in clinical trials. This cross-sectional study investigated associations between the omega-6/omega-3 PUFA ratio and somatic symptom disturbance and depressive symptoms in a community-based sample of 501 adults and determined whether these associations differed between adults with and without TMD or irritable bowel syndrome (IBS). Liquid chromatography tandem mass spectrometry quantified PUFAs in circulating erythrocytes. Somatic symptoms and depression were quantified using Symptom Checklist-90-Revised subscales. Presence or absence of TMD and IBS, respectively, were determined by clinical examination and Rome III screening questions. The standardized beta coefficient for the omega-6/omega-3 long-chain PUFA ratio was 0.26 (95% confidence limits (CL): 0.08, 0.43) in a multivariable linear regression model in which somatic symptom disturbance was the dependent variable. When modelling depressive symptoms as the dependent variable, the standardized beta coefficient was 0.17 (95% CL:0.01, 0.34). Both associations were stronger among TMD cases and IBS cases than among non-cases. Future randomized control trials that lower the omega-6/omega-3 PUFA ratio could consider somatic or depressive symptoms as a therapeutic target for TMD or IBS pain. PERSPECTIVE: In people with TMD or IBS, a high n-6/n-3 PUFA ratio was positively associated with somatic symptom disturbance and depressive symptoms. Both measures of psychological distress were elevated in people with painful TMD and IBS. Future randomized clinical trials will determine whether lowering the n-6/n-3 ratio is therapeutic for pain.
Identifiants
pubmed: 35477107
pii: S1526-5900(22)00304-2
doi: 10.1016/j.jpain.2022.04.006
pmc: PMC9561958
mid: NIHMS1801058
pii:
doi:
Substances chimiques
Fatty Acids, Omega-3
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
1737-1748Subventions
Organisme : NIDCR NIH HHS
ID : R21 DE029746
Pays : United States
Informations de copyright
Copyright © 2022 United States Association for the Study of Pain, Inc. Published by Elsevier Inc. All rights reserved.
Références
Biochem Soc Trans. 2017 Oct 15;45(5):1105-1115
pubmed: 28900017
Biomed Pharmacother. 2006 Nov;60(9):502-7
pubmed: 17045449
Open Heart. 2016 Sep 20;3(2):e000385
pubmed: 27843563
Am J Psychiatry. 1988 Nov;145(11):1358-68
pubmed: 3056044
Nutrients. 2021 Jul 09;13(7):
pubmed: 34371852
Metabolomics. 2012 Dec;8(6):1130-1147
pubmed: 23136559
Ann Neurol. 2013 Sep;74(3):490-5
pubmed: 23686636
Br J Nutr. 2018 Dec;120(11):1240-1251
pubmed: 30322410
Mol Pain. 2016 Mar 10;12:
pubmed: 27030719
Transl Psychiatry. 2014 Sep 09;4:e437
pubmed: 25203168
Matern Child Nutr. 2012 Jan;8(1):36-48
pubmed: 22136220
Am J Gastroenterol. 2016 Sep;111(9):1320-9
pubmed: 27377523
J Behav Med. 2018 Feb;41(1):43-51
pubmed: 28710565
J Lipid Res. 2010 Dec;51(12):3481-90
pubmed: 20664072
Basic Clin Pharmacol Toxicol. 2021 Jul;129(1):3-14
pubmed: 33905617
Front Cell Dev Biol. 2020 Dec 10;8:584206
pubmed: 33363143
Neurogastroenterol Motil. 2019 Feb;31(2):e13509
pubmed: 30549152
J Dent Res. 2007 Nov;86(11):1120-5
pubmed: 17959908
Nutrients. 2019 Apr 18;11(4):
pubmed: 31003520
Int J Mol Sci. 2021 Dec 16;22(24):
pubmed: 34948328
J Nutr Biochem. 2018 Aug;58:1-16
pubmed: 29621669
Transl Psychiatry. 2017 Aug 29;7(8):e1220
pubmed: 28850110
Headache. 2019 Nov;59(10):1687-1699
pubmed: 31524287
Mil Med. 2014 Nov;179(11 Suppl):117-28
pubmed: 25373095
BMC Psychiatry. 2020 May 20;20(1):248
pubmed: 32434488
Psychopharmacol Bull. 1973 Jan;9(1):13-28
pubmed: 4682398
Am J Clin Nutr. 1993 May;57(5 Suppl):801S-805S; discussion 805S-806
pubmed: 8475898
J Pain. 2011 Nov;12(11 Suppl):T12-26
pubmed: 22074749
J Pain. 2015 Aug;16(8):707-16
pubmed: 25958314
Curr Psychiatry Rep. 2019 Apr 27;21(6):38
pubmed: 31030284
Acta Psychiatr Scand. 2011 Oct;124(4):250-61
pubmed: 21916860
Br J Nutr. 2014 Feb;111(4):679-89
pubmed: 24063767
Nutrients. 2021 Mar 25;13(4):
pubmed: 33806078
Nutr Rev. 2022 May 9;80(6):1445-1458
pubmed: 34605891
JAMA Netw Open. 2018 Sep 7;1(5):e182327
pubmed: 30646157
Clin Nutr. 2020 Mar;39(3):765-773
pubmed: 31010701
J Pain. 2013 Dec;14(12 Suppl):T75-90
pubmed: 24275225
Psychiatry Res. 2010 Jul 30;178(2):230-5
pubmed: 20462641
Vitam Horm. 2021;115:129-172
pubmed: 33706946
Nat Metab. 2021 Jun;3(6):762-773
pubmed: 34140694
J Pain. 2013 Dec;14(12 Suppl):T102-15
pubmed: 24275218
J Oral Facial Pain Headache. 2020 Suppl;34:s85-s100
pubmed: 32975543
Prog Lipid Res. 2008 Mar;47(2):147-55
pubmed: 18198131
Transl Psychiatry. 2019 Aug 5;9(1):190
pubmed: 31383846
Am J Clin Nutr. 2007 Dec;86(6):1670-9
pubmed: 18065585
Psychother Psychosom. 2019;88(4):215-224
pubmed: 31269506
Neuropsychopharmacology. 2020 Jul;45(8):1330-1338
pubmed: 32375160
Am J Clin Nutr. 1991 Oct;54(4):668-73
pubmed: 1832813
J Oral Facial Pain Headache. 2014 Winter;28(1):6-27
pubmed: 24482784